Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock Market
31 janv. 2024 16h05 HE
|
TransCode Therapeutics, Inc.
Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement, Continued Listing on the Nasdaq Stock Market
TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer
29 janv. 2024 08h30 HE
|
TransCode Therapeutics, Inc.
TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer
TransCode Therapeutics Announces Closing of $7.25 Million Public Offering
22 janv. 2024 16h45 HE
|
TransCode Therapeutics, Inc.
TransCode Therapeutics closes public offering
TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering
18 janv. 2024 13h27 HE
|
TransCode Therapeutics, Inc.
TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering
TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO
12 janv. 2024 16h05 HE
|
TransCode Therapeutics, Inc.
TransCode Therapeutics Reports Further Restructuring to Reduce Expenses, Increased Focus on Planned Phase 1 Clinical Trial; Retirement of CEO
TransCode Therapeutics Announces 1-for-40 Reverse Stock Split
11 janv. 2024 08h00 HE
|
TransCode Therapeutics, Inc.
TransCode Announces Reverse Stock Split
TransCode Therapeutics Publishes Open Letter Outlining Company’s Progress and Objectives
04 janv. 2024 08h05 HE
|
TransCode Therapeutics, Inc.
An Open Letter to Shareholders of TransCode Therapeutics, Inc.
TransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138
12 déc. 2023 08h30 HE
|
TransCode Therapeutics, Inc.
BOSTON, Dec. 12, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported...
TransCode Therapeutics To Present Phase 0 Data at 2023 San Antonio Breast Cancer Symposium
05 déc. 2023 09h00 HE
|
TransCode Therapeutics, Inc.
BOSTON, Dec. 05, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, will present...
TransCode Therapeutics Announces Closing of $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
04 déc. 2023 16h10 HE
|
TransCode Therapeutics, Inc.
BOSTON, Dec. 04, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics,...